A continuous nonradioactive assay for RNA-dependent RNA polymerase activity.
Current assays for the activity of viral RNA-dependent RNA polymerases (RdRps) are inherently end-point measurements, often requiring the use of radiolabeled or chemically modified nucleotides to detect reaction products. In an effort to improve the characterization of polymerases that are essential to the life cycle of RNA viruses and develop antiviral therapies that target these enzymes, a continuous nonradioactive assay was developed to monitor the activity of RdRps by measuring the release of pyrophosphate (PP(i)) generated during nascent strand synthesis. A coupled-enzyme assay method based on the chemiluminescent detection of PP(i), using ATP sulfurylase and firefly luciferase, was adapted to monitor poliovirus 3D polymerase (3D(pol)) and the hepatitis C virus nonstructural protein 5B (NS5B) RdRp reactions. Light production was dependent on RdRp and sensitive to the concentration of oligonucleotide primer directing RNA synthesis. The assay system was found to be amenable to sensitive kinetic studies of RdRps, requiring only 6nM 3D(pol) to obtain a reliable estimate of the initial velocity in as little as 4 min. The assay can immediately accommodate the use of both homopolymer and heteropolymer RNA templates lacking uridylates and can be adapted to RNA templates containing uridine by substituting alpha-thio ATP for ATP. The low background signal produced by other NTPs can be corrected from no enzyme (RdRp) controls. The effect of RdRp/RNA template preincubation was assessed using NS5B and a homopolymer RNA template and a time-dependent increase of RdRp activity was observed. Progress curves for a chain terminator (3(')-deoxyguanosine 5(')-triphosphate) and an allosteric NS5B inhibitor demonstrated the predicted time- and dose-dependent reductions in signal. This assay should facilitate detailed kinetic studies of RdRps and their potential inhibitors using either standard or single-nucleotide approaches.
Lahser
Frederick C
FC
Department of Antiviral Therapeutics, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Malcolm
Bruce A
BA
D000494:Allosteric Regulation; D049454:Firefly Luciferin; D016174:Hepacivirus / Q000378:metabolism; D008156:Luciferases; D009690:Nucleic Acid Conformation; D017955:Poliovirus / Q000201:enzymology; D012313:RNA / Q000378:metabolism; D012324:RNA-Dependent RNA Polymerase / Q000032:analysis*; D013997:Time Factors; D017361:Viral Nonstructural Proteins / Q000032:analysis / Q000378:metabolism
D017361:Viral Nonstructural Proteins; D049454:Firefly Luciferin; D012313:RNA; D008156:Luciferases; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase